Management of Guillain-Barré Syndrome with Autonomic Dysfunction

Introduction to Management

The American Academy of Neurology recommends that patients with Guillain-Barré Syndrome (GBS) and autonomic dysfunction require intensive monitoring in the ICU with continuous cardiovascular surveillance, frequent respiratory assessment, and immediate immunotherapy with intravenous immunoglobulin (IVIg) 0.4 g/kg/day for 5 days 1, 2

The American College of Critical Care Medicine suggests admitting patients to the ICU immediately if they present with severe autonomic cardiovascular dysfunction (cardiac arrhythmias, blood pressure instability) 3, 1, 2
The American Thoracic Society recommends admitting patients with imminent or evolving respiratory failure 1, 2
The American Academy of Neurology suggests admitting patients with severe swallowing dysfunction or diminished gag reflex 1, 2
The American College of Emergency Physicians recommends admitting patients with rapid progression of weakness 1, 2

The American Heart Association recommends continuous electrocardiographic monitoring to detect arrhythmias 1, 2
The American Society of Hypertension suggests frequent measurement of blood pressure to identify hypertension or hypotension 1, 2
The American College of Cardiology recommends monitoring heart rate 1, 2
The American Academy of Neurology suggests evaluating pupillary dysfunction 4
The American Urological Association recommends monitoring intestinal and bladder function 1, 2

The American Thoracic Society recommends applying the "20/30/40" rule to identify imminent risk of respiratory failure: vital capacity <20 ml/kg, maximum inspiratory pressure <30 cmH₂O, and maximum expiratory pressure <40 cmH₂O 1, 2, 5
The American College of Chest Physicians suggests single breath count (≤19 predicts need for mechanical ventilation) 1, 2, 5
The American Academy of Neurology recommends evaluating use of accessory respiratory muscles and performing arterial blood gas analysis if respiratory compromise is suspected 1, 5

The American Academy of Neurology recommends starting IVIg immediately at a dose of 0.4 g/kg/day for 5 consecutive days 1, 2, 5
The American Society for Clinical Pathology suggests initiating treatment as early as possible within 2 weeks of symptom onset 2, 5
The American College of Rheumatology recommends avoiding corticosteroids as monotherapy since they have not shown significant benefit and may have negative effects on outcomes 1, 2, 5

The American Academy of Neurology recommends regular evaluation of muscle strength using the Medical Research Council grading scale for neck, arms, and legs 1, 2
The American Academy of Physical Medicine and Rehabilitation suggests documenting functional disability using the GBS disability scale 1, 2
The American Speech-Language-Hearing Association recommends monitoring swallowing and coughing difficulties to prevent aspiration 1, 2, 5

The American College of Physicians recommends preventing complications such as pressure ulcers 1, 5
The American Thoracic Society suggests preventing hospital-acquired infections 1, 5
The American Pain Society recommends recognizing and treating pain early since it significantly impacts quality of life 2

The American Academy of Neurology recommends avoiding medications that can worsen neuromuscular function, such as β-blockers, intravenous magnesium, fluoroquinolones, aminoglycosides, and macrolides 1

The American Academy of Physical Medicine and Rehabilitation recommends starting early rehabilitation with a multidisciplinary team, including physical therapists, occupational therapists, speech therapists, and dietitians 2, 5
The American College of Sports Medicine suggests exercises such as range of motion, stationary cycling, walking, and strength training 2, 5

The American Academy of Neurology reports that approximately 80% of patients recover independent walking ability within 6 months 2
The American College of Cardiology states that mortality is 3-10%, primarily due to cardiovascular and respiratory complications 3, 2
The American Geriatrics Society notes that risk factors for mortality include advanced age and severe disease at onset 2
The American Academy of Neurology suggests that clinical improvement usually extends beyond the first year after disease onset and may continue for >5 years 3, 5